Rein Therapeutics Inc. Stock Analysis & AI Score
Rein Therapeutics Inc. (RNTX) has an ST Score of 40.2 (C), driven by its Forecast (A) and held back by its Momentum (D). Analysts rate it Buy with a $6.00 price target (+706.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Rein Therapeutics Inc. (RNTX) has an ST Score of 40.2 (C), driven by its Forecast (A) and held back by its Momentum (D). Analysts rate it Buy with a $6.00 price target (+706.5% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD
All factor grades
- ForecastA
- Financial StrengthB-
- ValuationC+
- GrowthC-
- ProfitabilityD+
- MomentumD
- Piotroski2/9
Contact
RNTX stock: frequently asked questions
What is RNTX's ST Score?
Rein Therapeutics Inc. (RNTX) has an ST Score of 40.2 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RNTX a buy, hold, or sell?
Analysts rate RNTX a Buy, with a price target of $6.00 (+706.5% vs the current price). Our ST Score grades it C (40.2/100). The ST Score is a data-driven signal, not a recommendation.
What are RNTX's factor grades?
Valuation C+, Profitability D+, Financial Strength B-, Momentum D, Growth C-, Forecast A.
What is RNTX's valuation grade?
Rein Therapeutics Inc. (RNTX) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RNTX's growth grade?
Rein Therapeutics Inc. (RNTX) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RNTX's profitability grade?
Rein Therapeutics Inc. (RNTX) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RNTX's financial strength grade?
Rein Therapeutics Inc. (RNTX) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RNTX?
The average analyst price target for Rein Therapeutics Inc. (RNTX) is $6.00 from 2 analysts, which is +706.5% versus the recent price of $0.74.
What is RNTX's Piotroski score?
Rein Therapeutics Inc. (RNTX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.